RnRMarketResearch.com adds “Paraganglioma (Glomus Jugulare Tumor) – Pipeline Review, H1 2015” report to its store. The report provides an overview of the paraganglioma therapeutic pipeline.

Dallas, TX -- (SBWire) -- 02/11/2015 --The report "Paraganglioma (Glomus Jugulare Tumor) – Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Paraganglioma (Glomus Jugulare Tumor). Paraganglioma is an unusual tumor that develop in cells of peripheral nervous system. Paraganglioma is mainly noncancerous tumor of the middle ear. Most people with paraganglioma grow only one tumor in their lifetime. The cause of paraganglioma (glomus jugulare tumor) is unknown.

Complete report is available
http://www.rnrmarketresearch.com/paraganglioma-glomus-jugulare-tumor-pipeline-review-h1-2015-market-report.html

The report also reviews key players involved in the therapeutic development for Paraganglioma (Glomus Jugulare Tumor) and special features on late-stage and discontinued projects. Companies discussed in this Paraganglioma (Glomus Jugulare Tumor) – Pipeline Review, H1 2015 report include AstraZeneca PLC, Novartis AG, Pfizer Inc., Progenics Pharmaceuticals, Inc.

Symptoms of Paraganglioma (Glomus Jugulare Tumor) are difficulty swallowing, dizziness, hearing problems or loss, hearing pulsations in the ear, hoarseness, pain, weakness or loss of movement in the face. Drug profiles discussed in this report includes dovitinib lactate, everolimus, iobenguane sulfate I 131, sunitinib malate, vandetanib. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269532 . (This is a premium report priced at US$2000 for a single user License.)

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of content

List of Tables
Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor), H1 2015
Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Products under Development by Companies, H1 2015
Paraganglioma (Glomus Jugulare Tumor) - Pipeline by AstraZeneca PLC, H1 2015
Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Novartis AG, H1 2015
Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Pfizer Inc., H1 2015
Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Progenics Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Paraganglioma (Glomus Jugulare Tumor) Therapeutics - Recent Pipeline Updates, H1 2015

List of Figures
Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor), H1 2015
Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Explore more reports on Cancer Drugs Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs

Releated Reports on Cancer Drugs:

EpiCast Report: Colorectal Cancer – Epidemiology Forecast to 2023

Epidemiologists forecast that the number of total diagnosed incident cases of CRC in the 8MM is expected to grow from 758,062 cases in 2013 to 1,016,937 cases in 2023 at a rate of 3.41% per year during the forecast period. The number of diagnosed prevalent cases in the 8MM is expected to increase by 34.1% over the next decade from 2,583,156 cases in 2013 to 3,464,998 cases in 2023.

Get report details
http://www.rnrmarketresearch.com/epicast-report-colorectal-cancer-epidemiology-forecast-to-2023-market-report.html

Hodgkin Lymphoma – Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma. Companies discussed in this report includes 4SC AG, Acetylon Pharmaceuticals, Inc., Actinium Pharmaceuticals, Inc., Affimed Therapeutics AG, Aptose Biosciences Inc., AVEO Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Inc., Dynavax Technologies Corporation, Gamida Cell Ltd., Incyte Corporation, Johnson & Johnson, MABLife S.A.S, Merck & Co., Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Pharmacyclics, Inc., Philogen S.p.A., Seattle Genetics, Inc., Sigma-Tau S.p.A., Spectrum Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Syndax Pharmaceuticals, Inc., Takeda Oncology, Tekmira Pharmaceuticals Corp., TG Therapeutics, Inc.

Get report details
http://www.rnrmarketresearch.com/hodgkin-lymphoma-pipeline-review-h1-2015-market-report.html